Circle Pharma, Inc., a clinical-stage biopharmaceutical company developing next-generation macrocycle therapeutics to target cancer, announced the appointment of Rob Lauzen as its new Chief Financial Officer. Lauzen joins Circle Pharma with extensive experience in finance and capital strategy across the life sciences industry. He most recently served as CFO at Prilenia Therapeutics, where he led the company’s financial operations, capital planning, and investor relations initiatives.
Health Technology Insights: Verily Accelerates Precision Health AI With NVIDIA
David J. Earp, J.D., Ph.D., President and Chief Executive Officer of Circle Pharma, said that Rob’s addition to the leadership team comes at a pivotal time for the company. “We are pleased to welcome Rob as we continue advancing our lead program, CID-078, through Phase 1 clinical development,” Earp stated. “His depth of experience in corporate finance, strategic planning, and capital markets will be critical as we expand our pipeline of innovative oral macrocycle therapies that target cyclins, which are key cancer drivers long considered difficult to treat. Rob’s leadership will help us maintain our strong momentum and support our long-term growth objectives.”
Before joining Circle Pharma, Lauzen held senior roles at Dyne Therapeutics as Vice President of Investor Relations and Head of Financial Planning & Analysis. Earlier in his career, he worked at Morgan Stanley in the healthcare investment banking division, where he advised clients on major financial transactions, including over $185 billion in mergers and acquisitions and $10 billion in equity offerings. Lauzen earned a Bachelor of Arts in Engineering Sciences from Dartmouth College.
Health Technology Insights: Innovaccer Brings Multimodal AI to the Frontlines of Care with NVIDIA
Commenting on his new role, Lauzen said, “I am excited to be part of Circle Pharma during this important phase of its growth. The company’s strong scientific platform and its focus on cyclin-driven cancers position it to make a real impact on patients’ lives. I look forward to helping advance Circle’s mission of turning groundbreaking science into innovative therapies that provide meaningful clinical benefits and long-term value for patients and stakeholders.”
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 29 October 2025
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
